A Pre-Cellular Therapy Observational Study in Early Huntington's Disease (PRE-CELL)

• ClinicalTrials.gov Identifier: NCT01937923
• Recruitment Status: Completed
• First Posted: September 10, 2013
• Last Update Posted: November 1, 2016
• Sponsor: University of California, Davis
• Information provided by (Responsible Party): University of California, Davis

Study Description

Brief Summary:

This observational study will establish a clinical baseline and measure changes over time in movement, thinking, behavior, brain imaging, blood and spinal fluid markers in subjects with early stage Huntington's disease. Participants enrolled in this study may be eligible to participate in a future planned study of stem cell therapy for Huntington's Disease (HD).

In-person study visits occur at screening, baseline, and every 6 months thereafter for a minimum of 12 months, with interim phone call assessments.

Condition or disease
Huntington Disease

Detailed Description:

In PRE-CELL the investigators propose to enroll a cohort of early-stage HD patients in a prospective observational study designed to characterize clinical, neuro-imaging, laboratory and biomarker correlates of disease progression over 12-18 months. Subjects who complete a minimum of 12 months' participation in this trial will be candidates for enrollment in the future planned Phase 1 trial of intrastriatal delivery of mesenchymal stem cell (MSC)/Brain-derived neurotrophic factor (BDNF).

Study Design

• Study Type: Observational
• Actual Enrollment: 29 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: A Pre-Cellular Therapy Observational Study in Early Huntington's Disease
• Study Start Date: August 2013
• Actual Primary Completion Date: July 2016
• Actual Study Completion Date: July 2016

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :

1. Rate of change from baseline in white matter volume on magnetic resonance imaging (MRI) brain scan. [ Time Frame: Baseline and 12 or 18 months ]

Secondary Outcome Measures :

1. Rate of change from baseline on the UHDRS total motor score [ Time Frame: Baseline and 12 or 18 months ]
2. Rate of change from baseline on the Total Functional Capacity score [ Time Frame: Baseline and 12 or 18 months ]

Biospecimen Retention:   Samples Without DNA

Safety labs: Complete blood count, comprehensive metabolic panel, international normalized ration, partial thromboplastic time, thyroid stimulating hormone, urinalysis, HIV screen.

Biomarkers: Brain-derived neurotrophic factor (BDNF) in cerebrospinal fluid (CSF) and Plasma, BDNF related and Huntington's Disease (HD) specific gene transcription markers in CSF and blood, Small molecule markers of HD in CSF and plasma

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Non-Probability Sample

Study Population

Subjects will be primarily recruited from the Huntington's disease clinic in the University of California, Davis (UC Davis) department of neurology. We also plan to recruit participants from among northern California regional support groups, from letters to neurologists and psychiatrists who are treating patients with HD, from listing our study on clinical trials.gov, and at regional and national HD meeting presentations, and via print and video recordings on our website.

Criteria

Inclusion Criteria:

• Men or women age 18 and older, English speaking, able to give informed consent and comply with study procedures.
• HD diagnosis confirmed with genetic testing demonstrating CAG trinucleotide repeat length (CAGn) greater than 37
• Early stage HD with Total Functional Capacity (TFC) score of 9-13
• Demonstrable motor signs with a Unified Huntington's Disease Rating Scale (UHDRS) diagnostic confidence level of 4
• Must have a caregiver or informant able to give feedback about the participant and willing to report observations about subject on standardized forms.
• Subjects of child bearing potential must agree to adequate birth control measures including intrauterine device, hormone therapy, hormone rings or barrier methods including foams/gels AND condoms.

Exclusion Criteria:

• Very early disease without demonstrable motor signs (diagnostic confidence level < 4)
• Significant cognitive impairment or dementia as defined by Montreal Cognitive Assessment (MoCA) score < 12.
• Moderate or advanced disease with TFC < 9
• Concurrent active unstable psychiatric disease including history of suicide attempts within the last year, major personality or psychiatric disorders.
• History of concurrent serious medical illness such as HIV or current anti-retroviral treatment, cancer, major cardiac, pulmonary, immunological or other organ disease.
• History of coagulopathy, bleeding disorder, or concurrent use of blood thinners.
• History of brain tumor, serious traumatic brain injury with coma, or history of brain surgery.
• Any comorbid condition that presents an unacceptable health risk to the patient in the investigator's view
• Clinically significant laboratory test abnormalities, including full blood count, chemistry panel, liver function tests, Prothrombin time/international normalized ratio (PT/INR), lipid panel, electrocardiogram (EKG), or chest x-ray as judged by the investigator.
• Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with safety or adherence to study requirements.
• History or documentation of contraindication for MRI brain scan, including the presence of pacemaker, neurostimulator, aneurysm clips, artificial heart valves, cochlear implants, metal fragments in the eyes, orbits or skin or any other known contraindication to MRI.
• Any significant MRI brain scan findings other than those characteristic of HD.
• Any contraindications to surgery or to the use of general anesthesia, including allergy.
• History of use of any investigational agent within 60 days prior to enrollment
• History of current or previous gene therapy or stem cell therapy.
• History of previous or current treatment with cytokines
• History of sensitivity to ganciclovir.
• Pregnant and/or lactating women

Contacts and Locations

Locations

United States, California

UC Davis Medical Center, Clinical Research Center

Sacramento, California, United States, 95817

Sponsors and Collaborators

University of California, Davis

Investigators

• Principal Investigator: Vicki Wheelock, MD; University of California, Davis

More Information

Publications:

Tempkin T, DeCarli C, Scher L, Farias S, Duffy A., Fink K, Annett G, Brunberg J, Yarborough M, Hersch S, Stout J, Alyward E, Martin A, Kjer L, Swadell D, Nolta J, Wheelock V. PRE-CELL: A Pre-Cellular Observational Study in Early Huntington's Disease. Eight Annual Huntington's disease Clinical Research Symposium, Minneapolis MN, November 2014; Neurotherapeutics 2015;12(1): 263-284

Wheelock V, Tempkin T, Duffy A, Martin A, Mooney L, Scher L, Farias S, Swadell D, DeCarli C, Brunberg J, Li C-S, Yarborough M, Dayananthan A, Stout J, Hersch S, Aylward E, Fink KD, Annett G and Nolta J. "PRE-CELL: Preparing for a future planned Phase 1 trial of genetically-modified stem cells over-expressing BDNF in patients with Huntington's disease." Ninth Annual Huntington's Disease Clinical Research Symposium (October 2015), Tampa FL

Moscovitch-Lopatin M, DiFiglia M, Kegel-Gleason K, Ritch JJ, Rosenthal SJ, Sapp E, Wheelock V, Duffy A, Chopra V, Rosas HD, Hersch SM. "A Novel Translational Bioassay for Conformers of Mutant Huntingtin." Ninth Annual Huntington's Disease Clinical Research Symposium (October 2015), Tampa FL

• Responsible Party: University of California, Davis
• ClinicalTrials.gov Identifier: NCT01937923
• Other Study ID Numbers: 455690; DR2A-05415 ( Other Grant/Funding Number: CIRM )
• First Posted: September 10, 2013
• Last Update Posted: November 1, 2016
• Last Verified: October 2016

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Additional relevant MeSH terms:

Huntington Disease; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Heredodegenerative Disorders, Nervous System; Neurodegenerative Diseases; Genetic Diseases, Inborn; Cognition Disorders; Neurocognitive Disorders; Mental Disorders; Dementia; Chorea; Dyskinesias